Press release from Companies: DanCann Pharma A/S: Tetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain

Press release from Companies: DanCann Pharma A/S: Tetra Bio-Pharma Announces Start of the REBORN1(C) Clinical Trial

Press release from Companies: DanCann Pharma A/S have signed a definitive distribution agreement with Tetra Bio-Pharma Inc. for the exclusive distribution of Reduvo™ Adversa® and Qixleef™ in Scandinavia and Germany

Press release from Companies: DanCann Pharma A/S har skrivit på ett slutgiltigt distributionsavtal med Tetra Bio-Pharma Inc. för exklusiv distribution av Reduvo™ Adversa® och Qixleef™ i Skandinavien och Tyskland

Press release from Companies: DanCann Pharma A/S appoints Christian Carlsen as new Board Member

Press release from Companies: DanCann Pharma A/S: Tetra Bio-Pharma Submits Request for Scientific Advice to Malta Medicines Authority

Press release from Companies: DanCann Pharma A/S issues warrants to the Board of Directors

Press release from Companies: DanCann Pharma A/S Annual General Meeting 2021 and decisions by the Board of Directors

Press release from Companies: DanCann Pharma A/S: Market update for penetration of the Danish market, cf. the Danish Pilot Programme with medical cannabis

Press release from Companies: DanCann Pharma A/S: Tetra Bio-Pharma Provides an Update on its U.S. REBORN1 Clinical Trial

Press release from Companies: DanCann Pharma A/S has pressed the start button in BIOTECH PHARM1

Press release from Companies: DanCann Pharma A/S appoints Helle Bjerregaard as Head of Quality